期刊
TRENDS IN ENDOCRINOLOGY AND METABOLISM
卷 20, 期 8, 页码 374-379出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2009.04.007
关键词
-
资金
- Swiss National Science Foundation [3200B0-106098/1, 320000-117998/1]
- Oncosuisse [OCS-01551-08-2004]
- EMDO Stifttmg
- NIH [HL69846, DK68575]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069846] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068575] Funding Source: NIH RePORTER
2-Methoxyestradiol (2-ME) is a biologically active metabolite of 17 beta-estradiol that appears to inhibit key processes associated with cell replication in vitro. The molecule has been suggested to have potent growth-inhibitory effects on proliferating cells, including smooth muscle cells and endothelial cells, and may be antiangiogenic. Because of these potential roles for 2-ME, its lack of cytotoxicity and low estrogenic activity, we hypothesize that 2-ME could be a valuable therapeutic molecule for prevention and treatment of cardiovascular diseases. Whether 2-ME is as effective in vivo as it is in vitro at modulating vascular processes remains controversial. Here we discuss recent developments regarding mechanisms by which 2-ME might regulate vascular activity and angiogenesis and speculate on the therapeutic implications of these developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据